Needham & Company Maintains an 'Underperform' on Immunogen (IMGN); T-DM1 Data Encouraging, Awaiting Further Data Updates to Pivotal Trial
Tweet Send to a Friend
Needham & Company maintains an 'Underperform' on Immunogen Inc. (NASDAQ: IMGN).
Needham analyst says, "We maintain our UnderPerform rating for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "We maintain our UnderPerform rating for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
